Oxygen carriers free of cells in transfusion medicine;Importância dos carreadores de oxigênio livre de células

Revista Brasileira de Hematologia e Hemoterapia

Volumn 29, Issue 4, 2007, Pages 394-405

  Novaretti, Marcia Cristina Zago ^a,b,c  

^a Faculdade de Medicina

^b FUNDAÇÃO PRÓ SANGUE HEMOCENTRO DE SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

Artificial blood; Blood substitutes; Hemoglobin; Perfluorcarbon; Transfusion

Indexed keywords

EID: 41549096494     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-84842007000400014     Document Type: Review

References (163)

1. www.anvisa.gov.br [página acessada em 01 de julho de 2006]
2. www.IBGE.gov.br[página acessada em 09 de julho de 2006]
3. www.who.int [página acessada em 04 de julho de 2006]
4. www.health.state.mn.us, 2005.
5. Davey RJ. Overcoming blood shortages: Red blood cell and platelet substitutes and membrane modifications. Curr Hematol Rep 2004; 3(2):92-6.
6. aed. Philadelphia. Lippincott Williams & Wilkins 2006.p. 131-52.
7. a ed, Bethesda, MD:AABB Press 2005, p. 515-39.
8. Spahn DR, Casutt M. Eliminating blood transfusions: new aspects and perspectives. Anesthesiology. 2000;93:242-55.
9. Winslow R. Oxygen Transport Agents: A new approach to red blood cell alternatives. Transfusion. Alternatives in Transfusion Medicine. 2004;5(6):498-504.
10. Kjellstrom BT. Blood substitutes: Where do we stand today? J. Intern. Med. 2003;253:495-7.
11. Stowell CP, Levin J, Spiess BD, Winslow RM. Progress in the development of RBC substitutes. Transfusion. 2001;41:28-9.
12. Chang TM. A new red blood cell substitute. Crit. Care Med. 2004; 32:612-23.
13. Sakai H, Yuasa M, Onuma H, Onuma S. Takeoka, E. Tsuchida. Synthesis and physicochemical characterization of a series of hemoglobin-based oxygen carriers: Objective comparison between cellular and acellular types. Bioconjugate Chem. 2000; 11:56-64.
14. Rabinovici R. The status of hemoglobin-based red cell substitutes. Reviews. 2001;3:691-7.
15. Stowell CP. Hemoglobin-based oxygen carriers. Curr. Opin. Hematol. 2002;9:537-43.
16. Cohn SL. Is blood obsolete? Current opinion. Journal of Trauma-Injury Infection & Critical Care. 1997;42(4):730-2.
17. Goorha YK, Deb P, Chatterjee T, Dhot PS, Prasad RS. Artificial blood. MJAFI 2003;59(1):45-50.
18. Amberson WR. Blood substitutes. Biological Reviews of The Cambridge Philosophical Society. 1937;12:48-52.
19. Amberson WR, Jennings JJ, Rhode CM. Clinical experience with hemoglobin-saline solutions. J Appl Physiol. 1949;1:469-89.
20. Tsai AG. Influence of cell-free Hb on local tissue perfusion and oxygenation in acute anemia after isovolemic hemodiluition. Transfusion. 2001;41:1290-8.
21. Alayash AI. Oxygen therapeutics: Can we tame haemoglobin? Nat Rev Drug Discov. 2004;3:152-9
22. Standl T. Artificial oxygen carriers: Hemoglobin-based oxygen carriers - Current Status 2004. Transfus. Med. Hemother. 2004; 21:262-8.
23. Ogata Y. Evaluation of human hemoglobin vesicle as an oxygen carrier: Recovery from hemorrhagic shock in rabbits. Polym. Adv. Technol. 2000;11:301-6.
24. Carmichael FJ. Recent development in hemoglobin-based oxygen carriers - an update on clinical trials. Transfus Apheresis Sci. 2001;24:17-21.
25. Chang TM. Modified hemoglobin-based blood substitutes: cross-linked, recombinant and encapsulated hemoglobin. Vox Sang. 1998;74(suppl 2):233-41.
26. Chang TMS. Semipermeable microcapsules. Science 1964; 146:524-5.
27. Bunn HF, Jandl JH. The renal handling of hemoglobin.Trans Assoc Am Physicians. 1968;81:147-52.
28. Clark LC, Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science. 1966;152:1755-6.
29. Scott MG, Kucik DF, Goodnough LT et al. Blood substitutes: evolution and future applications. Clin Chem. 1997;43:1724-31.
30. Hill SE. Oxygen therapeutics - Current concepts. Can. J. Anesth. 2001;48:S32-S40
31. Clark LC. Emulsion of perfluoronated solvents for intravenous gas transport. Fed Proc. 1981;34:1468-77.
32. Riess JG. Fluorocarbon-based oxygen carriers: new orientations. Artif Organs. 1991;15:408-13.
33. Lowe KC, Ferguson E. Benefit and risks perceptions in transfusion medicine: Blood and blood substitutes. J. Inter. Med. 2003;253:498-507.
34. Riess JG. Oxygen carriers ("blood substitutes") - raison d'etre, chemistry and some physiology. Chem. Rev. 2001;101:2797-2919.
35. Winslow RM. Current status of blood substitute research: Towards a new paradigm. J Intern. Med. 2003;253:508-17.
36. Niiler E. Setbacks for blood substitutes companies. Naut Biotechnol 2002;20:962-3.
37. Draft guidance for industry: Criteria for safety and efficacy evaluation of oxygen therapeutics as red blood cell substitutes; avalilability. FDA 2004 (69);208:62903-04
38. Winslow RM. Blood Substitutes. Adv. Drug Delivery Reviews 2002;40:131-42.
39. Chen HS, Yang ZH. Perfluorocarbon as blood substitute in clinical applications and in war casualties. In: Chang TMS, ed. Blood Substitutes. New York, NY: Marcel Dekker; 1989:403-9.
40. Creteur J, Vicent JL. Hemoglobin solutions. Crit Care Med. 2003; 31(suppl):707.
41. Vane LA, Funston JS, Kirschner R et al. Comparison of transfusion with DCLHb or pRBCs for treatment of intraoperative anemia in sheep. J Appl Physiol. 2002;92:343-53.
42. Winslow RM, Gonzales A, Gonzales ML et al. Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model. J Appl Physiol. 1998;85:993-1003.
43. Lee R, Neya K, Svizzero TA et al. Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions. J Appl Physiol. 1995; 79:236-342.
44. Sakai H, Masada Y, Takeoka S, Tsuchida E. Characteristics of bovine hemoglobin as a potential source of hemoglobin-vesicles for an artificial oxygen carrier. J. Biochem. 2002;131:611-17.
45. Haney CR, Buehler PW, Gulati A. Purification and chemical modifications of hemoglobin in developing hemoglobin based oxygen carriers. Adv Drug Deliv Rev. 2000;40:153-69.
46. Barve A, Sen AP, Saxena PR et al. Dose response effects of diaspirin crosslinked hemoglobin (DCLHb) on systemic hemodynamics and regional blood circulation in rats. Artf Cells Blood Substit Immobil Biotechnol. 1997;25:75-84.
47. Pape A, Kemming G, Meisner F et al. Diaspirin Cross-linked hemoglobin fails to improve left fluid resuscitation from hemorrhagic shock. Eur Surg Res. 2001;33:318-26.
48. Kumar A, Sen AP, Saxena PR et al. Resuscitation with diaspirin crosslinked hemoglobin increases cerebral and renal blood perfusion in hemorrhaged rats. Artf Cells Blood Substit Immobil Biotechnol. 1997;25:85-94.
49. Chappell JE, McBride WJ, Shackford SR. Diaspirin cross-linked hemoglobin resuscitation improves cerebral perfusion after head injury and shock. J Trauma. 1996;41:781-8.
50. Chappell JE, Shackford SR, McBride WJ. Effects of hemodilution with diaspirin cross-linked hemoglobin on intracranial pressure, cerebral perfusion pressure, and fluid requirements after head injury and shock. J Neurosurg. 1997;86:131-8.
51. Schubert A, Przybelski RJ, Eidt JF et al. Diaspirin-crosslinked hemoglobin reduces blood transfusion in noncardiac surgery : a multicenter, randomized, controlled, double-blinded trial. Anesth Analg. 2003;97:323-32.
52. Von Dobschuetz E, Hoffmann T, Messmer K. Diaspirin crosslinked hemoglobin effectively restores pancreatic microcirculatory failure in hemorrhagic shock. Anesthesiology. 1999;91:1754-62.
53. Wettstein R, Tsai AG, Erni D et al. Resuscitation with polyethylene glycol-modified human hemoglobin improves microcirculatory blood flow and tissue oxygenation after hemorrhagic shock in awake hamsters. Crit Care Med. 2003;31:1824-30.
54. Kidane A, McPherson T, Shin HS, Park K. Surface modification of polyethylene terephthale using PEG-Polybutadiene-PEG triblock copolymers. Colloids Surf. B. Biointerfaces. 2000;3-4:347-53.
55. Winslow R, Kramer G. Malmeide-polyethylene glycol modified human hemoglobin. Crit Care Med. 2003;31(12):2815-6.
56. Manjula B, Tsai A, Upadhya R, Perumalsamy K, Smith P, Malavalli A et al. Site-specific PEGylation of hemoglobin at Cys-93 (beta): Correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain. Bioconjug Chem 2003;14:464-72.
57. Winslow RM. MP4, a new nonvasoactive polyethylene glycolhemoglobin conjugate. Artif Organs. 2004;28:800-6
58. Kramer GC. Counterintuitive red blood cell substitute - Polyethylene glycol-modified human hemoglobin. Critical Care Medicine. 2003;31:1882-4.
59. Vandegriff K, Malavalli A, Wooldridge J, Lohman J, Winslow R. MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion. 2003; 43:509-16.
60. Wettstein R, Cabrales P, Erni D et al. Resuscitation from hemorrhagic shock with MalPEG-calbumin: comparison with MalPEG-hemoglobin. Shock. 2004;22(4):351-7.
61. Lee DH, Bardossy L, Peterson N et al. O-raffinose cross-linked hemoglobin improves the hemostatic defects associated with anemia and thrombocytopenia in rabbits. Blood. 2000;96:3630-6.
62. Leytin V, Mazer D, Mody M et al. Hemolink, an O-raffinose activation and function of human platelets in whole blood in vitro. Br J Haematol. 2003;120:535-41.
63. Stowell CP. What happened to blood substitutes? Tranfus Clin et Biol 2005;12:374-9.
64. Gould SA, Moore EE, Moore FA et al. Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery. J Trauma. 1997;43(2):325-31.
65. Gould SA, Moore EE, Hoyt DB et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg. 1998;187(2):113-20.
66. Gould SA, Moss GS. Clinical development of human polymerized hemoglobin as a blood substitute. World J Surg. 1996;20(9):1200-7.
67. Gould SA, Moore EE, Hyot DB et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. J Am Coll Surg. 2002;195(4):445-52.
68. Levy JH, Goodnough LT, Greilich PE et al. Polymerized bovine hemoglobin solution as replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg. 2002;124(1):35-42.
69. Kipnis K, King NM, Nelson RM. An open letter to institutional review boards considering Northfield Laboratories' PolyHeme trial. Am J Bioeth. May-Jun 2006;6(3):18-21.
70. Katz LM, Manning JE, McCurdy S et al. HBCO-201 improves survival in a swine model of hemorrhagic shock and liver injury. Resuscitation. 2002;54(1):77-87.
71. McNeil CJ, Smith LD, Jenkins LD et al. Hypotensive resuscitation using a polymerized bovine hemoglobin-based oxygen-carrying solution (HBOC-201) leads to reversal of anaerobic metabolism. J Trauma. 2001;50(6):1063-75.
72. Sprung J, Kindscher JD, Wahr JA et al. The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesth Analg. 2002;94(4):799-808.
73. Muir WW 3rd, de Morais HS, Constable PD. The effects of a hemoglobin-based oxygen carrier (HBOC-201) on left ventricular systolic function in anesthetized dogs. Vet Surg. 2000; 29(5):449-55.
74. Cheng DC, Mazer CD, Martineau R et al. A phase II doseresponse study of hemoglobin raffimer (Hemolink) in elective coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2004; 127(1):79-86.
75. Lieberthal W, Fuhro R, Freedman JE et al. O-raffinose crosslinking markedly reduces systemic and renal vasoconstrictor effects of unmodified human hemoglobin. J Pharmacol Exp Ther. 1999; 288(3):1278-87.
76. Inayat MS, Bernard AC, Gallicchio VS, Garvy BA, Elford HL, Oakley OR. Oxygen carriers: A selected review. Transf and Apher Sci 2006;34(1):25-32.
77. Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo - relations to circulation lifetime. J. Biol. Chem. 1992;267(26):18759-65.
78. Rudolph AS, Sulpizio A, Hieble P, MacDonald V, Chavez M, Feuerstein G. Liposome encapsulation attenuates hemoglobin-induced vasoconstriction in rabbit arterial segments. J. Applied Phys. 1997;82(6):1826-35.
79. Philips WT, Klipper RW, Awashi VD, Rudolph AS et al. Polyethylene glycol-modified liposome-encapsulated hemoglobin: A long circulating red cell substitute. J. Pharmacol. Exp. Ther. 1999; 288(2):665-70.
80. Teramura Y, Kanazawa H, Sakai H, Takeoda S, Tsuchida E. Prolonged oxygen-carrying ability of hemoglobin vesicles by coencapsulation of catalase in vivo. Bioconjugate Chem. 2003; 14(6):1171-6.
81. Juliano RL, Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem Biophys Res Commun. 1975;63(3):651-8.
82. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003;42(6):463-78.
83. Rudolph AS. Biomaterial biotechnology using self-assembled lipid microstructures. J. Cell. Biochem. 1994;56(2):183-7.
84. Arifin DR, Palmer AF. Determination of size distribution and encapsulation efficiencies of liposomes encapsulated hemoglobin by asymmetric flow field-flow fractionation and multi-angle light scattering. Biotech. Prog. 2003;19(6):1798-811.
85. Arifin DR, Palmer AF. Polymersomes encapsulated hemoglobin: a novel type of cellular-base artificial blood substitutes. Biomacromocules. (in press) 2005;6(4):2172-81.
86. Arifin DR, Palmer AF. Stability of liposome encapsulated hemoglobin dispersions. Art Cells Blood Subs Immobil Biotech. 2005;33(2):113-36.
87. Arifin DR, Palmer AF. Physical properties and stability mechanisms of poly(ethylene glycol) conjugated liposome encapsulated hemoglobin dispersion. Art Cells Blood Subs Imm Biotech. 2005; 33(2):137-62.
88. Farmer MC, Gaber BP. Liposome-encapsulated hemoglobin as an artificial oxygen-carrying system. Methods Enzymol. 1987; 149:184-200.
89. Chang TM. Future generations of red blood cell substitutes. J Int Med 2003;253(5):527-35.
90. McCarthy MR, Vandegriff KD, Winslow RM. The role of facilitated diffusion in oxygen transport by cell-free hemoglobin: implications for the design of hemoglobin-based oxygen carriers. Biophys Chem. 2001;30:103-17.
91. Awasthi VD, Garcia D, Goins BA, Philips WT. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int. J. Pharm. 2003;253(1-2):121-32.
92. Hoffman SJ, Looker DL, Roehrich JM, Cozart PE, Durfee SL et al. Expression of fully functional tetrameric human hemoglobin in Escherichia coli. Proc Natl Acad Sci USA. 1990; 87(21):8521-5.
93. Zuckerman SH, Doyle MP, Gorczynski R et al. Preclinical biology of recombinant human hemoglobin rHb1.1. Artif Cells Blood Substit Immobil Biotech. 1998;26(3):231-57.
94. Vasseur-Godbillon C, Sahu SC, Domingues E, Fablet C, Giovannelli JL, Tam TC et al. Recombinant hemoglobin betaG83C-F41Y. FEBS J. 2006;273(1):230-41.
95. Buehler PW, Alayash AI. Toxicities of hemoglobin solutions: in search of in-vivo model systems. Transfusion. 2004; 44(10):1516-30.
96. Standl TG, Reeker W, Redmann G et al. Haemodynamic changes and skeletal muscle oxygen tension during complete blood exchange with ultrapurified polymerized bovine haemoglobin. Intensive Care Med. 1997;23(8):865-72.
97. Palaparthy R, Saini BK, Gulati A. Modulation of diaspirin crosslinked hemoglobin induced systemic and regional hemodynamic response by ethanol in normal rats. Life Sci. 2001;68(12):1383-94.
98. de Figueiredo LF, Nelson SH, Mathru M et al. Effects of hemoglobin-based blood substitutes on vasoactivity of rat aortic rings. Artif Organs. 2001;25(11):928-33.
99. Kavdia M, Pittman RN, Popel AS. Theoretical analysis of effects of blood substitute affinity and cooperativity on organ oxygen transport. J. Appl. Physiol. 2002;96(6):2122-8.
100. Saxena R, Wijnhoud AD, Man in't Veld AJ et al. Effect of diaspirin cross-linked hemoglobin on endothelin-1 and blood pressure in acute ischemic stroke in man. J Hypertens. 1998;16(10):1459-65.
101. Winslow R, Intagietta M, Tsai A, Vandegriff K, Wettstein R. Autoregulation and vasoconstriction: Foundation for a new generation of blood substitutes. Blood 2002;100(11):210.11-16.
102. Alayash AI, Ryan BA, Fratantoni JC et al. Hemoglobin-based oxygen carriers (HBOCs): structural alterations that affect free radical generation. Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):277-81.
103. Sellke FW, Shafique T, Ely DL et al. Coronary endothelial injury after cardiopulmonary bypass and ischemic cardioplegia is mediated by oxygen-derived free radicals. Circulation. 1993; 88:395-400.
104. Alayash Al, Fratantoni JC, Bonaventura C et al. Consequences of chemical modifications on the free radical reaction of human hemoglobin. Arch Biochem Biophys. 1992;298(1):114-20.
105. Burhop K, Gordon D, Estep T. Review of hemoglobin-induced myocardial lesions. Artif Cells Blood Substit Immobil Biotechnol. 2004;32(3):353-74.
106. Baldwin AL, Wiley EB, Alayash AI. Comparison of effect of two hemoglobin-based O (2) carriers on intestinal integrity and microvascular leakage. Am J Physiol Heart Circ Physiol. 2002; 283(4):H1292-H301. 107. Niwa K, Ikebuchi K, Fujihara M et al. Inflammatory cytokine production in whole blood modified by liposome- encapsulated hemoglobin. Artif Cells Blood Substit Immobil Biotechnol. 1998;26(5-6):559-70.
107. McFaul SJ, Bowman PD, Villa VM. Hemoglobin stimulates the release of proinflammatory cytokines from leukocytes in whole blood. J Lab Clin Med. 2000;135(3):263-9.
108. Kalfin RE, Engelman RM, Rousou JA et al. Induction of interleukin-8 expression during cardiopulmonary bypass. Circulation. 1993; 88(5 Pt 2):II401-6.
109. Kavdia M, Tsoukias NM, Popel As. Model of nitric oxide diffusion in an arteriole: impact of hemoglobin-based blood substitutes. Am J Physiol Heart Circ Physiol. 2002;282(6):H2245-H53.
110. Misra HP, Fridovich I. The generation of superoxide radical during the autoxidation of hemoglobin. J Biol Chem. 1972; 247(21):6960-2.
111. Dong F, Hall CH, Golech SA, Philbin NB, Rice JP, Gurney J et al. Immune effects of resuscitation with HBOC-201, a hemoglobin-based oxygen carrier, in swine with moderately severe hemorrhagic shock from controlled hemorrhage Shock. 2006; 25(1):50-5.
112. Ortegon DP, Davis MR, Dixon PS et al. The polymerized bovine hemoglobin-based oxygen-carrying solution (HBOC-201) is not toxic to neural cells in culture. Journal of Trauma - Injury infection & Critical Care. 2002;53(6):1068-72.
113. Geyer RP, Taylor K, Duffett EB et al. Successful complete replacement of the blood of living rats with artificial substitutes. Fed Proc. 1973;32:927.
114. Gould SA, Rosen AL, Sehgal LR et al. Fluosol- DA as a red cell substitute in acute anemia. N Engl J Med. 1986;314(26):1653-6.
115. Stefaniszyn HJ, Wynands JE, Salerno TA. Initial Canadian experience with artificial blood (Fluosol-DA 20%) in severe anemic patients. J Cardiovasc Surg. 1985;26(4):337-42.
116. Spence RK, McCoy S, Costabile J et al. Fluosol-DA 20% in prehospital resuscitation. Crit Care Med. 1989;17:166-72.
117. Spencer RK, McCoy S, Constabile J, et al. Fluosol DA-20 in the treatment of severe anemia: randomized, controlled study of 46 patients. Crit Care Med. 1990;18(11):1227-30
118. Kerins DM. Role of perflurocarbon Fluosol-DA in coronary angioplasty. Am J Med Sci 1994;307(3):218-21.
119. Winslow R. Blood substitutes. Academic Press, 2005;576pgs.
120. Wahr JA, Trowborst A, Spencer RK. A pilot study of the efficacy of an oxygen carrying emulsion, Oxygent, in patients undergoing surgical blood loss [abstract]. Anesthesiology. 1994;8:A313.
121. Maesvsky E, Ivanitsky G, Bogdanova L, Axenova O, Karmen N et al. Clinical results of Perftoran application: Present and future. Artif Cells Blood Substit Immobil Biotechnol. 2005; 33(1):37-46.
122. Tremper KK, Vercelotti GM, Hammerschmidt DE. Hemodynamic profile of adverse clinical reactions to Fluosol-DA 20%. Crit Care Med. 1984;12(5):428-31.
123. Ingram DA, Forman MB, Murray JJ. Activation of complement by Fluosol attributable to the pluronic detergent micelle structure. J Cardiovasc Pharmacol. 1993;22(3):456-61.
124. Fujita J, Suzuki C, Organa R. Effect of Fluosol-DA on the reticuloendothelial system function in surgical patients. In: Bolin RB, Geyer RP, Nemo GJ, Eds. Advancer in blood substitute research. Progress in clinical and biological research. Vol.122. New York, NY: Alan R Liss Inc; 1983:265.
125. Winslow RM. Current status of oxygen carriers (blood substitutes). Vox Sang. 2006;91(2):102-10.
126. Smith DJ, Lane TA. Effect of a high concentration perfluorocarbon emulsion on a platelet function. Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):1045-9.
127. Hammerschmidt DE, Vercelloti GM. Limitation of complement activation by perfluorocarbon emulsions: superiority of lecithin-emulsified preparations. Biomater Artif Cells Artif Organs. 1988; 16(1-3):431-8.
128. Bottalico LA, Betensky HT, Min YB et al. Perfluorochemical emulsions decrease Kupffer cell Phagocytosis. Hepatology. 1991;14(1):169-74.
129. Hong F, Shastri KA, Logue GL et al. Complement activation by artificial blood substitute Fluosol: in vitro and in vivo studies. Transfusion. 1991;31(7):642-7.
130. Ingram DA, Forman MB, Murray JJ. Phagocytic activation of human neutrophils by the detergent component of Fluosol. Am J Pathol. 1992;140(5):1081-7.
131. FDA Guidance for industry. 2004;17:1-256.
132. Winslow R. Alternative oxygen therapeutics: products, status of clinical trials, and future prospects. Curr Hematol Rep. 2003;2(6):503-10.
133. Jahr JS, Nesargi SB, Lewis K et al. Blood substitutes and oxygen therapeutics: an current status. Am J Ther. 2002;9(5):437-43.
134. 2 delivery by cell-free hemoglobin: A new basis for oxygen therapeutics. Am J Physiol Heart Circ Physiol. 2003; 285 (4):H1411-9.
135. Sakai H, Takeoka S, Wettstein R, Tsai AG, Intaglietta M, Tsuchida E. Systemic and microvascular responses to hemorrhagic shock and resuscitation with Hb vesicles. Am J Physiol Heart Circ Physiol. 2002;283(3): H1191-9.
136. Moore EE. Blood substitutes: The future is now. J Am Coll Surg. 2003;196(1):1-17.
137. Moore EE, Cheng AM, Moore HB, Masuno T, Johnson JL. Hemoglobin based oxygen carriers in trauma care: scientific rationale for the US Multicenter prehospital trial. World J Surg 2006;30(7):1247-57.
138. Krieter H, Hagen G, Waschke KF et al. Isovolemic hemodilution with a bovine hemoglobin-based oxygen carrier: effects on hemodynamics and oxygen transport in comparison with a nonoxygencarrying volume substitute. J Cardiothor Vasc Anesth. 1997; 11(1):3-9.
139. Pittman RN, Miller KB, Tait PH. Effect of hemoglobin solutions as hemodiluents on capillary oxygen tension. Adv Exp Med Biol. 2003;510:83-8.
140. Cabrales P, Sakai H, Tsai AG et al. Oxygen transport by low and normal P50 hemoglobin vesicles in extreme hemodilution. Am J Physiol Heart Circ Physiol. 2005;288(4):H1885-92.
141. Meisner FG, Kemming GI, Habler OP et al. Diaspirin crosslinked hemoglobin enables extreme hemodilution beyond the critical hematocrit. Crit Care Med. 2001;29:829-38.
142. Mullon J, Giacoppe G, Clagett C et al. Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia. N Engl J Med. 2000;342(22):1638-43.
143. Sakai H, Takeoka S, Park SI, Kose T et al. Surface modification of hemoglobin vesicles with Poly (ethylene glycol) and effects on aggregation, viscosity and blood flow during 90% exchange transfusion in anesthetized rats. Bioconjugate Chem. 1997;8(1):23-30.
144. Daugherty WP, Levasseur JE, Sun D et al. Perfluorocarbon emulsion improves oxygenation and mitochondrial function after fluid percussion brain injury in rats. Neurosurgery. 2004; 54 (5):1223-30.
145. Buehler PW, Haney CR, Gulati A, Ma L, Hsia CJ. Polynitroxyl hemoglobin: a pharmacokinetic study of covalently bound nitroxides to hemoglobin platforms. Free Radic Biol Med. 2004; 37(1):124-35.
146. Dromsky DM, Fahlman A, Spiess BD. Treatment of severe decompression sickness in swine with Oxygent, a perfluorocarbon emulsion. Aviat Space Environ Med. 2004;75(4):301-5.
147. Teicher BA. Use of perfluorochemical emulsions in cancer therapy. Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):875-82.
148. Teicher BA.Combination of perfluorochemical emulsions and carbogen brething with cancer chemotherapy. Artif Cells Blood Substit Immobil biotechnol 1994;22(4):1109-20.
149. Spiess BD, Cochran RP. Perfluorocarbon emulsions and cardiopulmonary bypass: a technique for the future. J Cardiothorac Vasc Anesth. 1996;10(1):83-9.
150. Mun KC, Bae JH, Suh SI et al. Effect of modified polyhemoglobin on the oxidative damage after ichemia-reperfusion in the liver. Transplant Proc 2003; 35:126-7.
151. Creteur J, Zhang H, De Backer D et al. Diaspirin cross-linked hemoglobin improves oxygen extraction capabilities in endotoxic shock. J Appl Physiol. 2000;89(4):1437-44.
152. Anton N, Hitzler JK, Kavanagh BP. Treatment of life-threatening post-haemorrhagic anaemia with cell free haemoglobin solution in an adolescent Jehovah's Witness. Br J Haematol. 2002; 118 (4):1183-6.
153. Cothrem CC, Moore EE, Long JS, Haenel JB, Johnson JL, Ciesla DJ. Large volume polymerizes haemoglobin solution in a Jehovah's Witness following abruptio placentae. Transfus Med. 2004;14(3):241-6.
154. Allison G, Feeney C. Successful use of a polymerized hemoglobin blood substitute in a critically anemic Jehovah's Witness. South Med J. 2004;97(12):1257-8.
155. Lanzkron S, Moliterno AR, Norris EJ et al. Polymerized human Hb use in acute chest syndrome: a case report. Transfusion. 2002; 42(11):1422-7.
156. Behan M, O'Connell D, Mattrey RF, Carney DN. Perfluorooctylbromide as a contrast agent for CT and sonography: preliminary clinical results. AJR Am J Roentgenol. 1993 160(2):399-405.
157. Fruman SA, Harned RK 2nd, Marcus D et al. Perfluoroctyl bromide as a blood pool contrast agent for computed tomographic angiography. Acad Radiol. 1994 Oct;1(2):151-3.
158. Caruthers SD, Neubauer AM, Hockett FD et al. In vitro demonstration using 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla. Invest Radiol. 2006;41(3):305-12.
159. Kluger R, Zhang J. Hemoglobin dendrimers: functional protein clusters. J Am Chem Soc. 2003;21;125(20):6070-1.
160. Garratty G. Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs. Transfus Med Rev. 2004;18(4):245-56.
161. Twyman LJ, Ge Y. Porphyrin cored hyperbranched polymers as heme protein models. Chem Commun (Camb). 2006 21; (15):1658-60.
162. Winslow RM. alphaalphaa-crosslinked Hemoglobin: was failure predicted by preclinical testing? Vox Sang. 2000;79 (1):1-20.
163. Keipert PE. Oxygen therapeutics ("Blood Substitutes") where are they, and what can we expect? Adv Exp Med. Biol. 2003; 540:207-13.